Migraine Without Aura Clinical Trial
Official title:
Personalised Internet-based Treatment From a Biopsychosocial Perspective for Migraine Patients and Its Feasibility in Primary Care
Verified date | October 2022 |
Source | Vastra Gotaland Region |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An individualised internet-based treatment from a biopsychosocial perspective for patients with migraines in primary care has been developed within the Vastra Gotaland region in 2019. The treatment program is called Learning to live with migraines, and goes by the acronym "I am" (Internet Approach to Migraine). In a pilot study, the treatment programme and its feasibility in primary care will be evaluated. It is hoped that the intervention "I am" can educate patients about their illness and help the patient manage migraine attacks so that the likelihood of difficulty and frequency of migraine attacks does not increase, as well as provide an increased function and quality of life.
Status | Completed |
Enrollment | 29 |
Est. completion date | October 14, 2022 |
Est. primary completion date | October 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Women and men - Age18 to 65 - Diagnosis migraine with (G43.0) or without aura (G43.1) - 3-15 migraine days a month - Access to computer/tablet or smartphone with bankid and internet connection Exclusion Criteria: - Ongoing malignant disease - Other migraine diseases - Moderate to severe psychiatric problems such as depression or anxiety disorder - Neuropsychiatric conditions - Psychosis disorders - Addiction - Personality disorders - People who cannot read, speak or understand the Swedish language - Ongoing psychological/psychotherapeutic treatment |
Country | Name | City | State |
---|---|---|---|
Sweden | FoU primary care Södra Älvsborg | Boras | Sven Eriksonsplatsen 4 |
Lead Sponsor | Collaborator |
---|---|
Vastra Gotaland Region |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Migraine Diary - change through week 2-10, and to 3 months follow up | Frequency and severity of migraine attacks monthly: will take place via a Migraine Diary. Questions to answer; Migraine pain signal?
When, day and time? Where does it hurt? Tick: Right temple, Left temple, Neck Inside the head, Area around the eye , other How's the pain? (Pulsating, burning, stinging, idling, stabbing) Strength, pain? (0-10) discomfort? (0-10) How do I try to deal with the pain? What emergency medication did you take at the beginning of the migraine attack? How long did the migraine attack last? Pain peak (throughout migraine attack) 0-10 In total, how much emergency medicine have you taken throughout the migraine attack? Pre symptoms or other symptoms? |
Week 2-10 through the study and by 3 months follow up. The participant fills in a new form of the diary for each new attack. | |
Primary | Employment rate - change through week 1, week 10, and by 3 months follow up | Employment rate: measured in percent by questions put to the participant. | Week 1, week 10 and by 3 months follow up | |
Primary | Bulls eye - activation in valued direction -change through week 1 and week 10, and to 3 months follow up | Measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal & Melin, 2012). ) The self-assessment scale is divided into four value areas in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good criterion validity (Lundgren, Dahl & Hayes, 2008) | Week 1-10 through the study and by 3 months follow up | |
Secondary | Mental Health Continuum Short Form - Mental health and quality of life | Measured with Mental Health Continuum Short Form (MHC-SF). The self-assessment form consists of 14 questions that focus on emotional, psychological and social well-being and are considered to have good psychometric properties (Keyes, 2005). | Week 1 and week 10 and by 3 months follow up | |
Secondary | CORE-10 - A broader measure of mental health in terms of well-being, symptoms, function and risks | Measured with the Swedish version CORE-10. The self-assessment form consists of 10 questions, one of which measures suicidality (Elfström, M. L., Evans, C., Lundgren, J., Johansson, B., Hakeberg, M., & Carlsson, S. G. (2012).
Validation of the Swedish version of the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE). Clinical Psychology and Psychotherapy. Epub ahead of print. doi:10.1002/cpp.1788) |
Week 1 and week 10 and by 3 months follow up | |
Secondary | Self-Efficacy for Exercise Scale - in their ability to conduct physical exercise | Measured by the Swedish version of the Self-Efficacy for Exercise Scale (SEE-EN). The form contains nine questions about the patient's faith in broad physical activity under different circumstances. A sum is calculated between 0 and 90, where higher number means higher confidence.Resnick B, Jenkins L 2000 Testing the reliability and validity of the Self-efficacy for Exercise Scale. Nursing Research 49: 149-159).The form has been translated into Swedish and tested for validity and reliability for patients with heart disease (Cavrak A 2010 Test of the psychometric properties of the Swedish version of the Self-Efficacy for Exercise scale for patients in cardiac rehabilitation.
Masters Thesis, Uni-versity of Gothenberg.) And patients with long-term pain (Dahlbäck A, Andréll P, Varkey E. Reliability and Validity of the Swedish Version of the Self-Efficacy for Exercise Scale (SEE-SV) for Patients with Chronic Pain .2020 Unpublished manuscript). |
Week 1, week 5, week 10 and by 3 months follow up | |
Secondary | Five Facet Mindfulness Questionnaire - conscious | Measured using the Swedish version of the Five Facet Mindfulness Questionnaire (FFMQ_SWE). FFMQ originally created by Baer et al. (2006) is a self-assessment form that aims to measure the ability to conscious presence. FFMQ_SWE consists of 29 claims and can be estimated between 1-5 points. The higher the score, the higher the self-rated ability to conscious presence. The internal validity and reliability of FFMQ_SWE is good (Lilja et al., 2011). | Week 1, week 5, week 10 and by 3 months follow up | |
Secondary | Self-Compassion Scale - Self compassion | Measured with Self-Compassion Scale - Short Form (SCS-SF). SCS-SF consists of 12 statements and is an abbreviated version of Self compassion scale (Neff, KD (2003b). The development and validation of a scale to measure self-compassion. Self & Identity, 2 (3), 223-250. doi: 10.1080 / 15298860309027. Self-compassion is measured with a corpse scale between 1 (almost never) and 5 (almost always) and has 6 subscales. SCS-SF has been shown to have good internal consistency (a = .86) and constructivevalidity as it correlates positively with SCS (r = 0.97). However, the subscale score has been shown to have poorer internal consistency and SCS-SF is therefore only suitable for measuring general self-compassion (Raes et al., 2011). Swedish translation of SCS-SF has been shown to have moderate internal consistency (a = .68) (Almqvist & Johansson, 2016). | Week 1, week 5, week 10 and by 3 months follow up | |
Secondary | Exercise diary, condition | Cardio training is measured with exercise diary Exercise diary contains filling in; activity, date, set | Week 1-10 through the study and by 3 months follow up | |
Secondary | Two questions to Haskell 2007 - Physical activity | Physical activity issues according to Haskell 2007. Two questions. Five total points or more means that the physical activity level is considered regular and corresponds to the public health recommendation. Below 5 total points means that the physical activity level needs to be increased. | Week 1-10 through the study and by 3 months follow up | |
Secondary | Acceptance of the treatment | Measured with its own constructed form developed for the study. The form consists of four questions: Would you recommend the processing to someone else? How meaningful have you experienced the treatment scale 1-7, as well as two open questions answered in writing: what have you got out of the treatment? What has been less good about the treatment? | Week 10 and by 3 months follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01687660 -
Acupuncture for Migraine Prophylaxis
|
N/A | |
Completed |
NCT00363532 -
Functional MRI (fMRI) in CGRP Induced Migraine
|
N/A | |
Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
Completed |
NCT04533568 -
Ibuprofen in Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
Completed |
NCT04636359 -
Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging.
|
N/A | |
Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Completed |
NCT00380263 -
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
|
N/A | |
Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Recruiting |
NCT06414044 -
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
|
||
Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 |